S
Simona Iacobelli
Researcher at University of Rome Tor Vergata
Publications - 112
Citations - 4910
Simona Iacobelli is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 30, co-authored 102 publications receiving 3957 citations. Previous affiliations of Simona Iacobelli include Leiden University & Leipzig University.
Papers
More filters
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Rodrigo Martino,Simona Iacobelli,Ronald Brand,Thekla Jansen,Anja van Biezen,Jürgen Finke,Andrea Bacigalupo,Dietrich W. Beelen,J Reiffers,Agnès Devergie,Emilie Alessandrino,Ghulam J. Mufti,Renee M.Y. Barge,Jorge Sierra,Tapani Ruutu,Marc Boogaerts,Michele Falda,Jean Pierre Jouet,Dieter Niederwieser,Theo de Witte +19 more
TL;DR: Patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS.
Journal ArticleDOI
Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Jan Styczyński,Lidia Gil,Gloria Tridello,Per Ljungman,Per Ljungman,J. Peter Donnelly,Walter J.F.M. van der Velden,Hamdy Omar,Rodrigo Martino,Constantijn J. M. Halkes,Maura Faraci,Koen Theunissen,Krzysztof Kałwak,Petr Hubacek,Simona Sica,Chiara Nozzoli,Franca Fagioli,Susanne Matthes,Miguel Angel Diaz,Maddalena Migliavacca,Adriana Balduzzi,Agnieszka Tomaszewska,Rafael de la Cámara,Anja van Biezen,Jennifer Hoek,Simona Iacobelli,Hermann Einsele,Simone Cesaro +27 more
TL;DR: Investigation of Epstein-Barr virus-related posttransplant lymphoproliferative disorder after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting found reduction of immunosuppression was associated with improved outcome, whereas older age, extranodal disease, and acute graft-vs-host disease predicted poor outcome.
Journal ArticleDOI
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet,Simona Iacobelli,Philippe Moreau,Mamoun Dib,Ingrid Lafon,Dietger Niederwieser,Tamas Masszi,Jean Fontan,Mauricette Michallet,Alois Gratwohl,Giuseppe Milone,Chantal Doyen,Brigitte Pegourie,Roman Hájek,Philippe Casassus,Brigitte Kolb,Carine Chaleteix,Bernd Hertenstein,Francesco Onida,Heinz Ludwig,Nicolas Ketterer,Christian Koenecke,Marleen van Os,Mohamad Mohty,Andrew Cakana,Norbert Claude Gorin,Theo de Witte,Jean Luc Harousseau,Curly Morris,Gösta Gahrton +29 more
TL;DR: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher incidence of grade 3 neurotoxicity.
Journal ArticleDOI
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Dimitrios C. Mastellos,Bruno Garcia Silva,Benedito Antonio Lopes da Fonseca,NP Fonseca,Maria Auxiliadora-Martins,Sara Mastaglio,Annalisa Ruggeri,Marina Sironi,Peter Radermacher,Akrivi Chrysanthopoulou,Panagiotis Skendros,Konstantinos Ritis,Ilenia Manfra,Simona Iacobelli,Markus Huber-Lang,Bo Nilsson,Despina Yancopoulou,E. Sander Connolly,Cecilia Garlanda,Fabio Ciceri,Antonio M. Risitano,Rodrigo T. Calado,John D. Lambris +22 more
TL;DR: Early clinical results offer important insights into the differential mechanistic basis and underlying biology of C3 and C5 inhibition in COVID-19 and point to a broader pathogenic involvement of C 3-mediated pathways in thromboinflammation.